Chronic (permanent) Atrial Fibrillation. Chronic atrial fibrillation
Conditions
Interventions
This group will consist of 30 patients of permanent uncontrolled atrial fibrillation, fulfilling inclusion criteria and intolerant to beta blockers (patients having asthma, COPD, hypotension, peripher
This group also consists of 30 patients with uncontrolled permanent atrial fibrillation. Patients will be assigned this group after excluding any contraindication to beta blockers. After in
Sponsors
Pervaiz Ilahi Institute of Cardiology, QAMC, BVH, Bahawalpur
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Adult patients with ages greater than 18 years. Fulfilling the criteria of permanent atrial fibrillation. Resting heart rate (HR) greater than 110 beats per minute on ECG. Capable of willingly providing informed consent. No previous history of receiving pulmonary vein ablation.
Exclusion criteria
Exclusion criteria: Individuals who have a known allergy to drugs. Conditions such as decompensated heart failure and needing inotropic drugs or intravenous diuretics within one week before enrollment in study, being in (New York Heart Association) NYHA functional class IV, or being on the waiting list for a heart transplant. Hypertrophic obstructive cardiomyopathy, acute pericarditis, constrictive pericarditis, acute myocarditis. Patients with renal failure needing hemodialysis or with liver failure. Cardiovascular or other major surgery within one month before randomization. A severe comorbidity with a life expectancy of less than one year. Stroke, unstable angina, or acute myocardial infarction ( within the last four weeks). Pregnant or breastfeeding females. Medical factors that might account for inadequate heart rate regulation including conditions such as pheochromocytoma, fever, hyperthyroidism and anemia. Inability to attend the planned appointments outlined in the procedure.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Heart Rate control. Timepoint: Before intervention then 2 weeks and 4 weeks after intervention. Method of measurement: Electrocardiography (ECG). Heart rate will be measured by R wave method on a rhythm strip of 10 seconds ( no. of R waves in 10 seconds*6). | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood Pressure. Timepoint: Before intervention, then 2 weeks and 4 weeks after intervention. Method of measurement: BP will be measured using sphygmomanometer.;Bradycardia/Tachycardia. Timepoint: 2 weeks and 4 weeks after intervention. Method of measurement: ECG and history.;Syncope. Timepoint: 2 weeks and 4 weeks after intervention. Method of measurement: History.;Adverse Cardiovascular events. Timepoint: 2 weeks and 4 weeks after intervention. Method of measurement: History and medical record.;Treatment discontinuation. Timepoint: 2 weeks and 4 weeks after intervention. Method of measurement: History. | — |
Countries
Pakistan
Contacts
Public ContactDoctor Humna Chaudri
Pervaiz Ilahi Institute of Cardiology, QAMC, BVH, Bahawalpur
Outcome results
None listed